

Resource Summary Report

Generated by [NIF](#) on Aug 6, 2026

HOP-flash

RRID:Addgene_83467

Type: Plasmid

Proper Citation

RRID:Addgene_83467

Plasmid Information

URL: <http://www.addgene.org/83467>

Proper Citation: RRID:Addgene_83467

Insert Name: Multimerized TEAD binding sites in the promoter of CTGF with minimal promoter

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:26216901](#)

Vector Backbone Description: Backbone Marker:Promega; Backbone Size:4797; Vector Backbone:pGL3-basic; Vector Types:Luciferase; Bacterial Resistance:Ampicillin

Plasmid Name: HOP-flash

Record Creation Time: 20220422T222540+0000

Record Last Update: 20260801T081929+0000

Ratings and Alerts

No rating or validation information has been found for HOP-flash.

No alerts have been found for HOP-flash.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Meng F, et al. (2025) SARS-CoV-2 NSP13 interacts with TEAD to suppress Hippo-YAP signaling. *eLife*, 13.

Jiang D, et al. (2025) Doublecortin-like kinase 1 promotes stem cell-like properties through the Hippo-YAP pathway in prostate cancer. *International journal of medical sciences*, 22(2), 460.

Kim G, et al. (2024) Sirtuin 5-mediated deacetylation of TAZ at K54 promotes melanoma development. *Cellular oncology (Dordrecht, Netherlands)*, 47(3), 967.

de Jaime-Soguero A, et al. (2024) Developmental signals control chromosome segregation fidelity during pluripotency and neurogenesis by modulating replicative stress. *Nature communications*, 15(1), 7404.

Cui Y, et al. (2023) Yes-associated protein nuclear translocation promotes anabolic activity in human articular chondrocytes. *Osteoarthritis and cartilage*, 31(8), 1078.

Prokakis E, et al. (2023) RNF40 epigenetically modulates glycolysis to support the aggressiveness of basal-like breast cancer. *Cell death & disease*, 14(9), 641.

Liu L, et al. (2023) Identification and functional comparison of novel alternatively spliced isoforms of human YAP. *FEBS open bio*, 13(6), 1001.

Caire R, et al. (2022) YAP Transcriptional Activity Dictates Cell Response to TNF In Vitro. *Frontiers in immunology*, 13, 856247.

He D, et al. (2022) De novo pyrimidine synthesis fuels glycolysis and confers chemoresistance in gastric cancer. *Cancer letters*, 549, 215837.

Tripathi S, et al. (2022) TAZ exhibits phase separation properties and interacts with Smad7 and β -catenin to repress skeletal myogenesis. *Journal of cell science*, 135(1).

Ko EA, et al. (2022) Drug repositioning of polaprezinc for bone fracture healing. *Communications biology*, 5(1), 462.

Kim G, et al. (2021) PIN1 facilitates ubiquitin-mediated degradation of serine/threonine kinase 3 and promotes melanoma development via TAZ activation. *Cancer letters*, 499, 164.

Bhattacharya D, et al. (2020) Metabolic Reprogramming Promotes Neural Crest Migration via Yap/TeaD Signaling. *Developmental cell*, 53(2), 199.

Li D, et al. (2020) lncRNA USP2-AS1 promotes colon cancer progression by modulating Hippo/YAP1 signaling. *American journal of translational research*, 12(9), 5670.

Zhu B, et al. (2020) Silencing SAPCD2 Represses Proliferation and Lung Metastasis of Fibrosarcoma by Activating Hippo Signaling Pathway. *Frontiers in oncology*, 10, 574383.

Knyazeva A, et al. (2020) FLNC Expression Level Influences the Activity of TEAD-YAP/TAZ Signaling. *Genes*, 11(11).

Liu X, et al. (2020) Long Non-Coding RNA MAPK8IP1P2 Inhibits Lymphatic Metastasis of Thyroid Cancer by Activating Hippo Signaling via Sponging miR-146b-3p. *Frontiers in oncology*, 10, 600927.

Liu X, et al. (2019) miR-424-5p Promotes Anoikis Resistance and Lung Metastasis by Inactivating Hippo Signaling in Thyroid Cancer. *Molecular therapy oncolytics*, 15, 248.

Wang X, et al. (2019) ZNF280A Promotes Proliferation and Tumorigenicity via Inactivating the Hippo-Signaling Pathway in Colorectal Cancer. *Molecular therapy oncolytics*, 12, 204.

Wang MT, et al. (2019) Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. *Nature communications*, 10(1), 3055.